Brentuximab vedotin: Phase II started

Seattle Genetics began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate Adcetris every 3 weeks in about 40 patients. Adcetris is under FDA review as consolidation t...